| Literature DB >> 23560841 |
Chiara Genco1, Giuseppe Cabibbo, Marcello Maida, Giuseppe Brancatelli, Massimo Galia, Nicola Alessi, Giuseppe Butera, Claudio Genova, Piero Romano, Maurizio Raineri, Antonello Giarratano, Massimo Midiri, Calogero Cammà.
Abstract
Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.Entities:
Mesh:
Year: 2013 PMID: 23560841 DOI: 10.1586/era.13.21
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN: 1473-7140 Impact factor: 4.512